The Wyss Foundation
The Wyss Foundation is an independent non-profit organization based in Washington, D.C., established in 1998 by Hansjörg Wyss. Its mission is to preserve, protect, and restore public lands, waters, and open spaces in the American West, promoting ecological health across these landscapes. The foundation is dedicated to supporting innovative and enduring solutions that enhance lives, empower communities, and foster connections to the environment. Through its philanthropic efforts, the Wyss Foundation aims to address critical issues related to land and water conservation while strengthening community ties to natural resources. The foundation's activities are guided by its board members, who oversee the management of its assets.
Top Stages
2 past transactions
Children's Hospital of Philadelphia Foundation
Grant in 2024
The Children's Hospital of Philadelphia Foundation is a non-profit organization based in Philadelphia, Pennsylvania, established in 1983 to support The Children's Hospital of Philadelphia, the first hospital in the United States dedicated exclusively to pediatric care. Since its inception in 1855, the hospital has been a leader in pediatric medicine, driving medical innovations that have significantly improved healthcare outcomes for children. The foundation plays a crucial role in sustaining essential programs that are not covered by insurance, funding research, clinical education, and overall growth of the hospital. Through the philanthropic contributions of its donors, the foundation enhances the hospital's capacity to deliver exceptional patient care and advance pediatric healthcare initiatives.
Cutiss
Series B in 2020
Cutiss AG is a biotechnology company specializing in the bio-engineering of customized human skin grafts, known as denovoSkin. The innovative process begins with a small biopsy of healthy skin from the patient, which is then used to generate large quantities of grafts tailored to individual needs. This approach aims to minimize scarring following transplantation, making it particularly beneficial for patients with severe burns. denovoSkin has garnered recognition and received Orphan drug designation from Swissmedic, the European Medicines Agency, and the FDA for its potential in treating burn injuries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.